Form 4: Cullinan Therapeutics Director Stephen Webster Acquires Stock Options

Director Stephen Webster acquired options to purchase 15,806 shares of Cullinan Therapeutics common stock on June 26, 2024.

Summary

• Stephen Webster, a director of Cullinan Therapeutics, Inc. (CGEM), acquired stock options on June 26, 2024.
• The options grant the right to purchase 15,806 shares of CGEM's common stock at an exercise price of $16.50.
• The options vest in full on the earlier of June 26, 2025, or the date of the Issuer's next annual meeting, contingent upon Webster's continued service as a director.
• Following the transaction, Webster directly owns 15,806 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates